These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31099166)

  • 21. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
    Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
    Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
    Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
    BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
    Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
    Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
    Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B
    Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
    Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
    Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pediatric preclinical testing program: description of models and early testing results.
    Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
    Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
    Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
    Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
    Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entinostat for the treatment of breast cancer.
    Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
    Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
    Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
    J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol.
    Miyachi M; Tsuchiya K; Hosono A; Ogawa A; Koh K; Kikuta A; Hara J; Teramukai S; Hosoi H
    Medicine (Baltimore); 2019 Dec; 98(52):e18344. PubMed ID: 31876708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
    Yardley DA; Ismail-Khan RR; Melichar B; Lichinitser M; Munster PN; Klein PM; Cruickshank S; Miller KD; Lee MJ; Trepel JB
    J Clin Oncol; 2013 Jun; 31(17):2128-35. PubMed ID: 23650416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental chemotherapy and radiotherapy to paratesticular rhabdomyosarcoma.
    Motoyama T; Watanabe H; Watanabe T; Yamamoto T
    J Urol; 1989 Jan; 141(1):187-9. PubMed ID: 2908947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.